Axios @axios
A judge will soon determine whether Pfizer can pay Medicare patients' out-of-pocket expenses for one of its heart medications priced at $225,000 per year. It could spur a "gold rush" of pharma companies to cover Medicare copays for expensive drugs. https://t.co/rfhWouvZAl — PolitiTweet.org